Gilead Sciences, Inc. today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in ...
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old ...
7h
Hosted on MSNKrystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock UpKrystal Biotech KRYS reported fourth-quarter earnings per share of $1.52, which beat the Zacks Consensus Estimate of $1.29 as ...
The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.
Apellis (APLS) and Sobi announced the European Medicines Agency has validated an indication extension application for Aspaveli for the ...
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi ® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli ® (pegcetacoplan) ...
The EU regulates the authorisation of medicines at EU level by the European Medicines Agency or at national level by the competent authorities in EU countries. Special rules exist for the ...
The European Medicines Agency has started a review of medicines containing finasteride and dutasteride following concerns ...
9d
GlobalData on MSNEMA establish advisory portal for high-risk medical devicesThe EMA anticipates that the ability to access scientific advice will foster innovation among medical device manufacturers.
CHMP Adopts Positive Opinion for Aflibercept, Pegfilgrastim Biosimilars: On January 30, 2025, the European Medicines Agency (EMA) Committee ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results